The effect of N-Acetylcystein on prevention of Acute Renal injury due to Cyclosporine Administration in patients undergoing bone marrow transplantation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306031030N14

Enrollment

Registered

2013-06-06

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: AML. Condition 2: ALL. Condition 3: Acute Renal injury. Acute myeloblastic leukaemia Acute lymphoblastic leukaemia

Interventions

Intervention 1: N-acetyl cysteine IV 100mg/kg daily. Drug start on the morning before starting chemotherapy and will continue until day 15 after transplantation. Intervention 2: Placebo Start on the m

Treatment - Drugs

Placebo

N-acetyl cysteine IV 100mg/kg daily. Drug start on the morning before starting chemotherapy and will continue until day 15 after transplantation.

Placebo Start on the morning before starting chemotherapy and will continue until day 15 after transplantation.

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Patients with acute myeloid leukemia or acute lymphocytic leukemia 2- Full match Allogeneic Bone Marrow Transplantation 3- Age between 15-60 year old 4- Treatment of Cyclosporin after transplantation Exclusion criteria: 1- Patient under 15 year old 2- Patient with diabetes, chronic kidney disease, liver disorder or hypertension

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum Creatinin. Timepoint: 6 and 3 days before transplantation and 3, 9 and 5 day after transplantation. Method of measurement: Lab test.	—

Secondary

Measure	Time frame
Urine NGAL. Timepoint: 6 and 3 days before transplantation and 3, 9 and 5 day after transplantation. Method of measurement: Lab test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Ataei

Hematology Oncology and SCT Research Center

horcbmt@tums.ac.ir+98 21 8490 2635

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026